Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals, Inc. - Common Stock
(NQ:
ALNY
)
365.46
+9.93 (+2.79%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 21, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alnylam Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
20
21
Next >
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
January 29, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again
↗
January 12, 2024
There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst.
Via
Investor's Business Daily
Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association
January 09, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
January 07, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Analyst Expectations for Alnylam Pharmaceuticals's Future
↗
December 08, 2023
Via
Benzinga
Expert Ratings for Alnylam Pharmaceuticals
↗
November 15, 2023
Via
Benzinga
2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs
↗
January 04, 2024
A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,...
Via
Benzinga
Topics
ETFs
10 Health Care Stocks Whale Activity In Today's Session
↗
January 02, 2024
Via
Benzinga
Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback
↗
December 29, 2023
Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals.
Via
Benzinga
Earnings Outlook For Alnylam Pharmaceuticals
↗
November 01, 2023
Via
Benzinga
Expert Ratings for Alnylam Pharmaceuticals
↗
October 16, 2023
Via
Benzinga
Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential
↗
December 22, 2023
Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am
Via
Benzinga
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
December 13, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
3 biotech powerhouses poised to thrive amid sector rebound
December 08, 2023
If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader.
Via
MarketBeat
Topics
ETFs
Alnylam to Webcast Virtual R&D Day
December 06, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Why Newly Listed Korro Bio Shares Are Gaining Today
↗
December 04, 2023
H.C. Wainwright initiated coverage on Korro Bio Inc (NASDAQ: KRRO), a biotech company developing genetic medicines focused on editing ribonucleic acid (RNA) to treat various diseases.
Via
Benzinga
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023
November 30, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk
November 11, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shareholder Alert: Investigation over Possible Violations of Securities Laws
↗
November 08, 2023
San Diego, CA -- (SBWIRE) -- 11/08/2023 -- Alnylam Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
November 07, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
November 02, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year
October 26, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
October 25, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
October 25, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results
October 19, 2023
From
Alnylam Pharmaceuticals, Inc.
Via
Business Wire
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing
↗
October 18, 2023
The company can begin a pivotal study of its treatment for cardiomyopathy.
Via
Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
↗
October 11, 2023
Via
Benzinga
CSX To Rally Around 27%? Here Are 10 Other Analyst Forecasts For Wednesday
↗
October 11, 2023
Morgan Stanley cut Netflix, Inc. (NASDAQ: NFLX) price target from $450 to $430. Morgan Stanley analyst Benjamin Swinburne maintained an Equal-Weight rating. Netflix shares rose 0.8% to $375.51 in...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2023
↗
October 11, 2023
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
20
21
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
